scholarly journals Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy

2017 ◽  
Vol 28 ◽  
pp. v469 ◽  
Author(s):  
L. Crinò ◽  
P. Bidoli ◽  
F. Roila ◽  
E. Cortesi ◽  
M.C. Garassino ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Safety Data ◽  
Efficacy And Safety ◽  
Expanded Access ◽  
Expanded Access Programme ◽  
Access Programme

scholarly journals The European Ipilimumab Expanded Access Programme (EAP): Efficacy and Safety Data from the Italian Cohort of Patients with Pretreated, Advanced Melanoma

2012 ◽  
Vol 23 ◽  
pp. ix367-ix368 ◽  
Author(s):  
P.A. Ascierto ◽  
V. Chiarion Sileni ◽  
M. Del Vecchio ◽  
M. Altomonte ◽  
F. De Galitiis ◽  
...  
Keyword(s):  
Safety Data ◽  
Advanced Melanoma ◽  
Efficacy And Safety ◽  
Expanded Access ◽  
Expanded Access Programme ◽  
Access Programme ◽  
Italian Cohort

scholarly journals Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population

2016 ◽  
Vol 27 ◽  
pp. iv3 ◽  
Author(s):  
L. Crinò ◽  
P. Bidoli ◽  
A. Delmonte ◽  
F. Grossi ◽  
F. de Marinis ◽  
...  
Keyword(s):  
Real World ◽  
Safety Data ◽  
World Population ◽  
Efficacy And Safety ◽  
Expanded Access ◽  
Expanded Access Programme ◽  
Access Programme ◽  
Italian Cohort

scholarly journals Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

2014 ◽  
Vol 12 (1) ◽  
pp. 116 ◽  
Author(s):  
Paolo A Ascierto ◽  
Ester Simeone ◽  
Vanna Sileni ◽  
Jacopo Pigozzo ◽  
Michele Maio ◽  
...  
Keyword(s):  
Clinical Experience ◽  
Real World ◽  
Safety Data ◽  
Efficacy And Safety ◽  
Expanded Access ◽  
Expanded Access Programme ◽  
Access Programme
Sign in / Sign up

Export Citation Format

Share Document